Novo weathering the storm in Russia; Mylan and Gilead expand hep C licensing pact; NICE OKs Soliris;

> Novo Nordisk ($NVO) says it intends to stay in Russia for the "long haul" despite the country's ongoing economic downturn. Report

> Mylan ($MYL) is expanding its hep C licensing agreement with Gilead ($GILD) to include an investigational pan-genotypic prospect. Release

> The U.K.'s cost-effectiveness gatekeeper has approved Alexion's ($ALXN) Soliris in final guidance, making it the first med to pass through the watchdog's new assessment system for highly specialized technologies. Report

> GlaxoSmithKline ($GSK) has rolled out new respiratory treatments Arnuity Ellipta for asthma and Incruse Ellipta for COPD in the U.S. Release

> Purdue Pharma has launched Hysingla ER, a once-daily opioid with abuse-deterrent properties. Release

And Finally... Procter & Gamble's ($PG) ZzzQuil's Twitter feed came under fire last week for a tweet critics called sexist. More

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

A lawsuit says J&J helped doctors set up high-volume "infusion suites" and offered other services as kickbacks to amp up Remicade and Simponi…

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.